Research graph
References from ERG Orchestrates a Dedifferentiation–Senescence–Inflammation Triad in Prostate Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
10.1126/science.1117679 · 2005 · External reference
The molecular taxonomy of primary prostate cancer
10.1016/j.cell.2015.10.025 · 2015 · External reference
Integrative clinical genomics of advanced prostate cancer
10.1016/j.cell.2015.06.053 · 2015 · External reference
Punctuated evolution of prostate cancer genomes
10.1016/j.cell.2013.03.021 · 2013 · External reference
Complex patterns of ETS gene alteration arise during cancer development in the human prostate
10.1038/sj.onc.1210843 · 2008 · External reference
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications
10.1158/1078-0432.ccr-07-5194 · 2008 · External reference
A causal role for ERG in neoplastic transformation of prostate epithelium
10.1073/pnas.0711711105 · 2008 · External reference
ERG activates the YAP1 transcriptional program and induces the development of age-related prostate tumors
10.1016/j.ccell.2015.05.005 · 2015 · External reference
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
10.1038/nm.3216 · 2013 · External reference
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
10.1038/ng.371 · 2009 · External reference
ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer
10.1126/sciadv.adc9446 · 2023 · External reference
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
10.1038/ng.370 · 2009 · External reference
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression
10.1016/j.ccr.2010.03.018 · 2010 · External reference
Role of the TMPRSS2-ERG gene fusion in prostate cancer
10.1593/neo.07822 · 2008 · External reference
Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer
10.1016/j.ccell.2017.02.017 · 2017 · External reference
ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming
10.1172/jci137967 · 2020 · External reference
Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG
10.1073/pnas.1922159117 · 2020 · External reference
ERG-mediated coregulator complex formation maintains androgen receptor signaling in prostate cancer
10.1158/0008-5472.can-20-2044 · 2020 · External reference
ERG/AKR1C3/AR constitutes a feed-forward loop for AR signaling in prostate cancer cells
10.1158/1078-0432.ccr-14-2352 · 2015 · External reference
Oncogene-mediated alterations in chromatin conformation
10.1073/pnas.1112570109 · 2012 · External reference
Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype
10.1038/s41391-021-00364-x · 2021 · External reference
Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome
10.1158/0008-5472.can-16-0902 · 2016 · External reference
TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model
10.1371/journal.pone.0021650 · 2011 · External reference
ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer
10.1172/jci66666 · 2013 · External reference
TMPRSS2: ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells
10.18632/oncotarget.15931 · 2017 · External reference
TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation
10.1038/onc.2014.308 · 2015 · External reference
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor
10.7554/elife.13964 · 2016 · External reference
Centriolar distal appendages activate the centrosome-PIDDosome-p53 signalling axis via ANKRD26
10.15252/embj.2020104844 · 2021 · External reference
Hit and go CAS9 delivered through a lentiviral based self-limiting circuit
10.1038/ncomms15334 · 2017 · External reference
Easy quantitative assessment of genome editing by sequence trace decomposition
10.1093/nar/gku936 · 2014 · External reference
ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradation
10.1016/j.canlet.2022.215612 · 2022 · External reference
Trimmomatic: a flexible trimmer for Illumina sequence data
10.1093/bioinformatics/btu170 · 2014 · External reference
STAR: ultrafast universal RNA-seq aligner
10.1093/bioinformatics/bts635 · 2013 · External reference
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
10.1093/bioinformatics/btp616 · 2010 · External reference
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles
10.1073/pnas.0506580102 · 2005 · External reference
The Molecular Signatures Database (MSigDB) hallmark gene set collection
10.1016/j.cels.2015.12.004 · 2015 · External reference
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
10.1126/science.abe1505 · 2022 · External reference
Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling
10.1016/j.ccell.2017.09.003 · 2017 · External reference
Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer
10.1073/pnas.2415308122 · 2025 · External reference
Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis
10.1016/j.celrep.2022.110595 · 2022 · External reference
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
10.1126/science.aah4307 · 2017 · External reference
Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states
10.1038/s41467-021-27322-4 · 2022 · External reference
Single-cell and spatial transcriptomic profiling reveals epithelial functional states and fibroblast phenotypes in hormone therapy–naïve localized prostate cancer
10.1158/0008-5472.can-25-1202 · 2026 · External reference
The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data
10.1158/2159-8290.cd-12-0095 · 2012 · External reference
Integrative genomic profiling of human prostate cancer
10.1016/j.ccr.2010.05.026 · 2010 · External reference
recount3: summaries and queries for large-scale RNA-seq expression and splicing
10.1186/s13059-021-02533-6 · 2021 · External reference
pROC: an open-source package for R and S+ to analyze and compare ROC curves
10.1186/1471-2105-12-77 · 2011 · External reference
Robust enumeration of cell subsets from tissue expression profiles
10.1038/nmeth.3337 · 2015 · External reference
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
10.1016/j.cell.2025.07.042 · 2025 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation
10.1074/jbc.m010208200 · 2001 · External reference
Binding of TMPRSS2-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis
10.1016/j.molcel.2018.06.040 · 2018 · External reference
TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer
10.1158/1078-0432.ccr-18-0653 · 2018 · External reference
The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer?
10.1038/embor.2010.117 · 2010 · External reference
Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells
10.1371/journal.pgen.1009708 · 2021 · External reference
Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation
10.1074/jbc.m117.796458 · 2017 · External reference
Prostate carcinogenesis: inflammatory storms
10.1038/s41568-020-0267-9 · 2020 · External reference
Cells of origin for cancer: an updated view from prostate cancer
10.1038/onc.2012.541 · 2013 · External reference
Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin
10.1073/pnas.1318157111 · 2014 · External reference
Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis
10.1038/s41467-023-40352-4 · 2023 · External reference
The senescence-associated secretory phenotype: the dark side of tumor suppression
10.1146/annurev-pathol-121808-102144 · 2010 · External reference
Il1-induced Jak/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma
10.1158/2159-8290.cd-18-0710 · 2019 · External reference
A senescence restriction point acting on chromatin integrates oncogenic signals
10.1016/j.celrep.2024.114044 · 2024 · External reference
TGF-β signaling in health and disease
10.1016/j.cell.2023.07.036 · 2023 · External reference
P53: 800 million years of evolution and 40 years of discovery
10.1038/s41568-020-0262-1 · 2020 · External reference
ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L
10.1038/s41588-025-02289-w · 2025 · External reference
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer
10.1016/j.celrep.2021.109665 · 2021 · External reference
Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone
10.1200/jco.18.01777 · 2019 · External reference
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis
10.1016/s0002-9440(10)65517-4 · 1999 · External reference
Prostate cancer and inflammation: the evidence
10.1111/j.1365-2559.2011.04033.x · 2012 · External reference
Activation of NF-κB by TMPRSS2/ERG fusion isoforms through toll-like receptor-4
10.1158/0008-5472.can-10-2210 · 2011 · External reference
Toll-like receptor 4 signaling activates ERG function in prostate cancer and provides a therapeutic target
10.1093/narcan/zcaa046 · 2021 · External reference
IL-6 overexpression in ERG-positive prostate cancer is mediated by prostaglandin receptor EP2
10.1016/j.ajpath.2015.12.009 · 2016 · External reference
Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer
10.1073/pnas.2018976118 · 2021 · External reference
Club-like cells in proliferative inflammatory atrophy of the prostate
10.1002/path.6149 · 2023 · External reference
Differential effect of non-steroidal anti-inflammatory drugs aspirin and naproxen against TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer
10.3390/cancers15205054 · 2023 · External reference
Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status
10.1038/pcan.2015.49 · 2016 · External reference
Unmasking senescence: context-dependent effects of SASP in cancer
10.1038/s41568-019-0156-2 · 2019 · External reference
Senescence-associated reprogramming promotes cancer stemness
10.1038/nature25167 · 2018 · External reference
